Targeting ROR1 and a two-drug approach to cure CLL
Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
MURANO trial: revolutionizing the standard of care for relapsed CLL patients
Where are we with precision medicine for CLL?